B
Bull
Bull · 25%ENLV
$1.19
Szenariopreis
$1.280
0.000 (0.00%)Zum Schluss
Loading chart…
- High
- 1.310
- Open
- 1.270
- VWAP
- 1.26
- Vol
- 343.34K
- Mkt Cap
- 31.31M
- Low
- 1.200
- Amount
- 433.76K
- EV/EBITDA, TTM
- 0.00
Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.
AI analysis of Enlivex Ltd (ENLV)
buyEnlivex Therapeutics Ltd is a good buy right now due to its significant potential upside. The current price is $1.35, while analysts have set a target price of $80, indicating a potential upside of over 5,800%. Additionally, the company has reported a net asset value of $66.16 per share, which suggests that the stock is undervalued at its current price. However, there is a risk of volatility, as evidenced by the recent 8.16% decline over the past five days and a staggering 88.08% drop year-to-date.
Bewertungskennzahlen
The current forward P/E ratio for Enlivex Ltd (ENLV) is 0.00, compared to its 5-year average forward P/E of -2.88.
Alphio AI Price Scenarios for ENLV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.507-28seekingalphaEnlivex Plans $400M Private Placement of Shares
- 9.507-20seekingalpha
Enlivex Reports Net Asset Value of $66.16 per Share
9.007-14NewsfilterFDA Grants RMAT Designation to Allocetra™ for Knee Osteoarthritis
9.007-13NASDAQ.COMEnlivex Receives FDA RMAT Designation for Allocetra
2.007-10NASDAQ.COMEnlivex Shares Enter Oversold Territory
ENLV FAQ — answered by Alphio AI
Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Enlivex Therapeutics Ltd is a good buy right now due to its significant potential upside. The current price is $1.35, while analysts have set a target price of $80, indicating a potential upside of over 5,800%. Additionally, the company has reported a net asset value of $66.16 per share, which suggests that the stock is undervalued at its current price. However, there is a risk of volatility, as evidenced by the recent 8.16% decline over the past five days and a staggering 88.08% drop year-to-date.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.